CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-20.32%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.3B
AUM Growth
+$1.3B
(-23%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
7.98%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
86
New
8
Increased
9
Reduced
24
Closed
9
Top Buys
Top Sells
| 1 |
Beam Therapeutics
BEAM
|
$23.5M |
| 2 |
Aclaris Therapeutics
ACRS
|
$13.1M |
| 3 |
Revolution Medicines
RVMD
|
$11.1M |
| 4 |
Cytokinetics
CYTK
|
$11M |
| 5 |
Zymeworks
ZYME
|
$9.83M |
Sector Composition
| 1 | Healthcare | 98.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $99.3M | 7.63% | 3,700,000 +675,000 | +22% | +$18.1M |
|
2
Erasca
ERAS
$445M
| $90.3M | 6.94% | 10,505,554 +4 | +0% | +$34 |
|
3
Design Therapeutics
DSGN
$315M
| $83.3M | 6.39% | 5,156,994 -283,459 | -5% | -$4.58M |
|
|
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $68.9M | 5.29% | 1,823,444 -24,580 | -1% | -$928K |
|
|
GRNA
5
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
| $62M | 4.76% | +6,710,540 | New | +$62M |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $57.2M | 4.39% | 1,125,000 +500,000 | +80% | +$25.4M |
|
|
7
Revolution Medicines
RVMD
$7.1B
| $50.9M | 3.91% | 1,995,066 -436,786 | -18% | -$11.1M |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $45.4M | 3.49% | 4,682,874 +1,116,973 | +31% | +$10.8M |
|
9
Monte Rosa Therapeutics
GLUE
$296M
| $42.1M | 3.23% | 3,002,199 | – | – |
|
|
FMTX
10
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $37.8M | 2.91% | 4,068,351 -571,644 | -12% | -$5.32M |
|
11
Avidity Biosciences
RNA
$5.99B
| $37.2M | 2.85% | 2,012,115 | – | – |
|
12
Tango Therapeutics
TNGX
$747M
| $37.1M | 2.85% | 4,899,185 | – | – |
|
|
JBIO
13
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $33.6M | 2.58% | 1,830,691 | – | – |
|
14
MoonLake Immunotherapeutics
MLTX
$3.54B
| $33.3M | 2.55% | 3,280,000 +2,850,000 | +663% | +$28.9M |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $23.1M | 1.78% | 1,375,982 -27,349 | -2% | -$460K |
|
16
Stoke Therapeutics
STOK
$1.08B
| $22.9M | 1.76% | 1,087,807 -94,555 | -8% | -$1.99M |
|
|
CNTA
17
Centessa Pharmaceuticals
CNTA
$2.25B
| $22.3M | 1.71% | 2,489,894 | – | – |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $21.7M | 1.67% | 865,000 +465,000 | +116% | +$11.7M |
|
|
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
| $20.2M | 1.55% | 322,240 | – | – |
|
|
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $19M | 1.46% | +150,000 | New | +$19M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $18.5M | 1.42% | 1,000,000 +700,000 | +233% | +$12.9M |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $16M | 1.23% | 700,710 -408,514 | -37% | -$9.32M |
|
23
BridgeBio Pharma
BBIO
$9.89B
| $15.9M | 1.22% | 1,568,909 -100,000 | -6% | -$1.01M |
|
24
Adicet Bio
ACET
$59.9M
| $15M | 1.15% | 750,000 | – | – |
|
25
Immuneering
IMRX
$245M
| $14.9M | 1.14% | 2,302,626 | – | – |
|